Schering To Create Third R&D Facility Under N.J. Consolidation Program
Schering-Plough will develop its Summit site into the company's third major New Jersey R&D facility under a consolidation plan for its home state locations
You may also be interested in...
Roche is cutting its U.S. sales force by 10% before the end of the year
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials